Bispecific Antibodies Are Used As Therapeutic Drugs While Treating Viral Infections, Oncology, And Auto-Immune Diseases

 

Bispecific Antibodies

Bispecific antibodies are produced through cell fusion or recombinant DNA technologies. Bispecific antibodies are much more specific than monoclonal antibodies. Their applications in tumor immunotherapy are nearly limitless. As of today, seven bispecific antibodies have been approved by the FDA and EMA and over one hundred are in preclinical testing.

Bispecific antibodies were initially developed using the quadroma technology. They contain two distinct antigen-binding arms, which enable them to bind to the target antigen while also activating an effector cell, which kills tumor cells. The primary antigen on the surface of the effector cell is called CD3, which is a popular target of immune cells.

According to Coherent Market insights the Bispecific Antibodies Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028.

Many of these multi specific antibody formats have been developed over the past 30 years. These categories of antibodies are only a small subset. These formats have been used in the key growth area of the last two decades.

Bispecific Antibodies, or BsAbs, are antibodies that recognize two antigens at the same time. This fusion can be engineered using scFv at the C-terminus of an antibody. These types of antibodies are bispecific and bivalent. The first work describing the production of BsAbs came in 1961.

Currently, bispecific antibodies are being developed to target various cancers, including hematologic and solid tumors. Multiple potential Phase 1/2 clinical trials are underway for these antibodies. Bispecific antibodies work by targeting tumor cells expressing specific antigens. As these antibodies target tumor cells, they can kill them.

Bispecific antibodies target two antigens on the surface of cancer cells, which enhances their specificity and targetability. They also reduce off-target effects. Bispecific antibodies have the potential to bridge the gap between tumor cells and immune cells. They can prevent tumor growth while improving immune function in this manner.

CytomX Therapeutics, Inc., entered in a strategic collaboration agreement with Astellas Pharma Inc., in March 2020. The agreement will be focussing on research, discovery, development and commercialization of novel T-cell engaging bispecific antibodies which will be targeting tumor cell surface antigens and CD3 for treating cancer.